(Q35226211)

7 August 2017

1 reference

title

Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies (English)

1 reference

7 August 2017

0 references

3

Tobias Welte

1 reference

7 August 2017

Christian Krauth

1

1 reference

7 August 2017

Noushin Jalilvand

series ordinal

2

1 reference

7 August 2017

Reinhard Busse

series ordinal

4

1 reference

7 August 2017

publication date

1 January 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

21

1 reference

7 August 2017

issue

14

1 reference

7 August 2017

page(s)

1001-1024

1 reference

Increasing survival of Swedish patients with CF

7 August 2017

cites work

1 reference

12 December 2020

Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations

1 reference

12 December 2020

Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase.

1 reference

12 December 2020

Self-administration of intravenous antibiotics: an efficient, cost-effective home care program.

1 reference

12 December 2020

Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population

1 reference

12 December 2020

Outpatient intravenous medications in the management of cystic fibrosis

1 reference

12 December 2020

Intravenous antibiotics at home in children with cystic fibrosis.

1 reference

12 December 2020

High-technology in home care. An overview of intravenous therapy.

1 reference

12 December 2020

Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects.

1 reference

12 December 2020

[Continuous intravenous home treatment of airway infections using ceftazidime administration via portable pump in patients with cystic fibrosis; a multicenter study]

1 reference

12 December 2020

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

12 December 2020

[Continuous intravenous antibiotic home treatment in 11 patients with cystic fibrosis in The Northern Netherlands]

1 reference

12 December 2020

[Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment]

1 reference

12 December 2020

Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis

1 reference

12 December 2020

Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

1 reference

12 December 2020

Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis.

1 reference

12 December 2020

Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.

1 reference

12 December 2020

Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.

1 reference

12 December 2020

Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1.

1 reference

12 December 2020

Retrospective review of the effects of rhDNase in children with cystic fibrosis

1 reference

12 December 2020

Cystic fibrosis and the salt controversy

1 reference

12 December 2020

Self-administered home intravenous antibiotic therapy in bronchiectasis and adult cystic fibrosis

1 reference

12 December 2020

Home treatment of patients with cystic fibrosis using the 'Intermate': the first year's experience

1 reference

12 December 2020

Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion

1 reference

12 December 2020

Home intravenous antibiotic treatment in cystic fibrosis

1 reference

12 December 2020

Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group

1 reference

12 December 2020

The changing epidemiology of cystic fibrosis

1 reference

12 December 2020

The nonhospital costs of care of patients with CF in The Netherlands: results of a questionnaire

1 reference

12 December 2020

Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis

1 reference

12 December 2020

A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis

1 reference

12 December 2020

Survival estimates for adults with cystic fibrosis born in the United Kingdom between 1947 and 1967. The UK Cystic Fibrosis Survey Management Committee

1 reference

12 December 2020

Burkholderia cepacia in cystic fibrosis. Variable disease course.

1 reference

12 December 2020

Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients

1 reference

12 December 2020

Comment: cost of rhDNase in cystic fibrosis.

1 reference

12 December 2020

Expenditures for care of children with chronic illnesses enrolled in the Washington State Medicaid program, fiscal year 1993

1 reference

12 December 2020

Determinants of mortality from cystic fibrosis in Canada, 1970-1989.

1 reference

12 December 2020

Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis

1 reference

12 December 2020

DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. DNase National Study Group

1 reference

12 December 2020

[Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients. Results of a controlled prospective study]

1 reference

12 December 2020

Home care in cystic fibrosis patients

1 reference

12 December 2020

Pharmacological treatment of the biochemical defect in cystic fibrosis airways

1 reference

12 December 2020

Cystic fibrosis: current survival and population estimates to the year 2000.

1 reference

12 December 2020

Cystic fibrosis, intravenous antibiotics, and home therapy

1 reference

12 December 2020

Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease

1 reference

12 December 2020

Home intravenous antibiotic treatment of patients with cystic fibrosis

1 reference

12 December 2020

Physicians, pharmacists, and home infusion antibiotic therapy

1 reference

12 December 2020

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

1 reference

12 December 2020

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

12 December 2020

CFTR as a cAMP-dependent regulator of sodium channels

1 reference

12 December 2020

Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report

1 reference

12 December 2020

Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis

1 reference

12 December 2020

Targeting of dornase alpha therapy in adult cystic fibrosis.

1 reference

12 December 2020

A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients

1 reference

12 December 2020

Management of pulmonary disease in patients with cystic fibrosis

1 reference

12 December 2020

Effects of Recombinant Human DNase Therapy on Healthcare use and Costs in Patients with Cystic Fibrosis

1 reference

12 December 2020

Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada

1 reference

12 December 2020

Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease

1 reference

12 December 2020

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

1 reference

12 December 2020

The acute effects of nasal positive pressure ventilation in patients with advanced cystic fibrosis

1 reference

12 December 2020

Prediction of Mortality in Patients with Cystic Fibrosis

1 reference

12 December 2020

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

12 December 2020

Avoiding double-counting in pharmacoeconomic studies

1 reference

12 December 2020

The cost of medical care for patients with cystic fibrosis in a health maintenance organization

1 reference

12 December 2020

Feasibility and cost savings of intravenous administration of aminoglycosides in outpatients with cystic fibrosis

1 reference

12 December 2020

Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis.

1 reference

12 December 2020

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis

1 reference

12 December 2020

Changes in strategies for optimal antibacterial therapy in cystic fibrosis.

1 reference

12 December 2020

Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience.

1 reference

12 December 2020

Let parents give the care: iv therapy at home in cystic fibrosis.

1 reference

12 December 2020

The gender gap in cystic fibrosis survival.

1 reference

12 December 2020

Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee

1 reference

12 December 2020

Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment

1 reference

12 December 2020

10.2165/00019053-200321140-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

7 August 2017

1001164797

0 references

1 reference